Lupin’s NaMuscla gets EU approval to treat myotonia in adults with NDM
Date: 2019-01-10   Author: Pankaj Singh  Category: #news

Lupin’s NaMuscla gets EU approval to treat myotonia in adults with NDM

Lupin Limited has reportedly received the European Commission’s approval for its specialty drug NaMuscla used in the treatment of a rare neuromuscular disorder. As per trusted sources, Lupin is preparing to launch NaMuscla in Germany and the UK in the first quarter of 2019, while seeking partners to market the drug in the remaining European territories.

NaMuscla, or rather mexiletine, is commonly used for the treatment of symptoms of myotonia in adults suffering from nondystrophic myotonic disorders. NDM disorders comprise a group of rare and genetic neuromuscular disorders which result in the inability to relax the muscles after voluntary contraction.

The EC approval is based on the positive opinion provided by the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s scientific committee, in October 2018 and will be applicable to all 28 nations that belong to the European Union, Iceland, Liechtenstein, and Norway.

As per industry experts, the approval makes NaMuscla the first treatment to be licensed across the European Union to treat myotonia in adults suffering from NDM disorders. Recently, NaMuscla also had its orphan drug designation approved by the EMA’s Committee for Orphan Medicinal Products, cite credible sources.

Thierry Volle, President EMEA of Lupin Limited, was quoted saying that the company is rather delighted with EU’s approval. It represents a significant milestone for Lupin as it continues to build itself as a leading specialty pharmaceutical company committed to the development, commercialization, and registration of scientific therapies for unmet medical needs, Volle added.

According to sources familiar with the development, it was the Phase III clinical study that set the groundwork for the approval. The clinical trial diagnosed 25 participants with NDM disorders and symptomatic myotonia. Moreover, the company is also running a pediatric investigation plan for the drug, cite sources.

Lupin Limited’s shares spiked by 1.04 percent to INR 829.40 on the Bombay Stock Exchange, reported sources.

Source: http://healthcareopportunity.org/lupins-namuscla-gets-eu-approval-to-treat-myotonia-in-adults-with-ndm/



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Pay as a Service Market Size 2020: by Manufacturers, Countries, Type and Application
Author: Ashwin Naphade

Global Pay as a Service Market analysis report speaks about the manufacturing process. Global Pay as a Service market report analyses the market growth, trends, overview & forecast to 2024.The report covers key technological developments in th...


Building Automatic Management System Market: Global Analysis of Key Manufacturers, Dynamics & Forecast 2020-2025
Author: Ashwin Naphade

The Global Building Automatic Management System Market 2019-2024 Renders deep perception of the Market Segment by Regions, market status of the Building Automatic Management System on a global level that primarily aims the core regions which compr...


Cloud based Repository Services Market Size 2025 - BCloud based Repository Services Market Size 2025 - By Application, Type & Manufacturers Across North America, Europe, APAC, South America, MEAy Application, Type & Manufacturers Across North America, Europe, APAC, South America, MEA
Author: Ashwin Naphade

The Global Cloud based Repository Services Market Report includes a comprehensive analysis of the present industry status offering basic Cloud based Repository Services overview and then goes into each and every detail.

The report on Clo...